Pharmanutra Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Pharmanutra is forecast to grow earnings and revenue by 20.7% and 13.1% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 28.6% in 3 years.

Anahtar bilgiler

20.7%

Kazanç büyüme oranı

20.6%

EPS büyüme oranı

Personal Products kazanç büyümesi	7.7%
Gelir büyüme oranı	13.1%
Gelecekteki özkaynak getirisi	28.6%
Analist kapsamı	Low
Son güncelleme	10 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Sep 11

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Mar 10

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Feb 17

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Feb 01

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Jan 18

Is Pharmanutra (BIT:PHN) A Risky Investment?

Jan 04

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Dec 22

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Dec 08

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 23

Kazanç ve Gelir Büyüme Tahminleri

BIT:PHN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	148	25	23	27	2
12/31/2025	131	21	19	22	2
12/31/2024	114	17	17	20	2
6/30/2024	108	14	15	20	N/A
3/31/2024	101	11	2	12	N/A
12/31/2023	101	13	-1	12	N/A
9/30/2023	95	12	-5	12	N/A
6/30/2023	93	14	-19	12	N/A
3/31/2023	88	16	-15	14	N/A
12/31/2022	83	15	-9	17	N/A
9/30/2022	79	16	-5	19	N/A
6/30/2022	76	15	10	19	N/A
3/31/2022	73	15	14	20	N/A
12/31/2021	68	14	15	20	N/A
9/30/2021	65	14	13	16	N/A
6/30/2021	60	11	12	15	N/A
3/31/2021	57	14	13	15	N/A
12/31/2020	57	14	10	12	N/A
9/30/2020	58	14	11	11	N/A
6/30/2020	58	14	7	11	N/A
3/31/2020	55	9	4	9	N/A
12/31/2019	54	8	7	12	N/A
9/30/2019	49	8	3	8	N/A
6/30/2019	50	9	7	9	N/A
3/31/2019	48	9	6	8	N/A
12/31/2018	47	9	6	6	N/A
9/30/2018	44	8	5	6	N/A
6/30/2018	41	7	5	6	N/A
3/31/2018	40	6	N/A	6	N/A
12/31/2017	38	6	N/A	6	N/A
9/30/2017	37	5	N/A	N/A	N/A
6/30/2017	35	5	N/A	N/A	N/A
3/31/2017	34	4	N/A	N/A	N/A
12/31/2016	33	4	N/A	6	N/A
12/31/2015	26	3	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PHN's forecast earnings growth (20.7% per year) is above the savings rate (2.4%).

Kazançlar ve Piyasa: PHN's earnings (20.7% per year) are forecast to grow faster than the Italian market (7.3% per year).

Yüksek Büyüme Kazançları: PHN's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: PHN's revenue (13.1% per year) is forecast to grow faster than the Italian market (3.9% per year).

Yüksek Büyüme Geliri: PHN's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PHN's Return on Equity is forecast to be high in 3 years time (28.6%)

Pharmanutra Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased to €59.33

Price target increased to €50.67

Price target increased to €45.00

Recent updates

Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)

Upcoming dividend of €0.85 per share

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Investor sentiment improved over the past week

Price target increased to €59.33

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to €50.67

Investor sentiment improved over the past week

Price target increased to €45.00

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Upcoming dividend of €0.67 per share

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

New 90-day high: €33.70

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Market bids up stock over the past week

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: €28.80

Third quarter 2020 earnings released: EPS €0.18

New 90-day high: €27.20

First half earnings released

First half earnings released

New 90-day low - €22.40

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin